Multaq: Liver Failure, Stroke, Cardiovascular Death, or Interstitial Lung Disease
We are not accepting new cases at this time.
Multaq (dronedarone) is a drug used to treat abnormal heart rhythm in patients who have had an abnormal heart rhythm (atrial fibrillation or atrial flutter). Multaq can reduce the risk of being hospitalized for these heart problems.
Multaq is manufactured by the drug company Sanofi-Aventis, based in Paris, France.
In January 2011 the FDA issued a drug safety alert for Multaq concerning severe liver injury, such as liver failure requiring liver transplantation, associated with Multaq use.
In July 2011 the FDA issued a second and different drug safety alert for Multaq. This one had to do with its review of new data from a medical study which indicated there was a two-fold increase in death, as well as two-fold increases in stroke and hospitalization for heart failure in patients receiving Multaq compared to patients taking a placebo.
In December 2011 the FDA said Multaq increased the risk of serious cardiovascular events, including death, when used by patients in permanent atrial fibrillation (AF).
In September 2012 the FDA approved label changes for Multaq, including one about certain types of lung disease such as pneumonitis and pulmonary fibrosis being serious side effects of Multaq use.
Lastly, cases of renal impairment and kidney damage in patients using Multaq have been reported.
Our law firm represents people in personal injury and wrongful death cases that involve certain adverse medical events which might have been caused by Multaq, such as:
- Liver transplant
- Acute liver or hepatic failure
- Liver damage
- Liver disease
- Drug-induced hepatitis
- Renal impairment
- Kidney damage
- Cardiovascular (CV) death
- Heart Failure (HF) hospitalization
- Stroke (CVA)
- Lung / Pulmonary disease
- Pulmonary fibrosis
- Interstitial Lung Disease (ILD)
Recent Side Effects Case Evaluations
Multaq – Interstitial Lung Disease (ILD) / Pulmonary Fibrosis – 69 yr old man
Multaq – Pneumonitis – 60 yr old man
Multaq – Pulmonary Fibrosis resulting in Death – 73 yr old man
Multaq – Pulmonary Fibrosis resulting in Death – 78 yr old woman
Multaq – Pulmonary Fibrosis – 82 yr old woman
Multaq – Interstitial Lung Disease (ILD) – 78 yr old man
Multaq – Pneumonitis and Pulmonary Fibrosis; Death – 78 yr old woman
Multaq – Interstitial Lung Disease (ILD) resulting in Death – 84 yr old woman
Multaq – Interstitial Lung Disease (ILD) – 73 yr old woman
Multaq – Sudden Cardiac Arrest / Death – 51 yr old man
Multaq – Acute Liver Failure / Death – 81 yr old woman
Most Recent Article About This Drug
Multaq: Increased Risks Of Side Effects, Including Death, Outweigh Any Benefits Say Researchers Who Reviewed Clinical Data
In Addition, They Are Highly Critical Of Relationship The Sanofi Aventis Drug Company Had With Those Doctors Who Developed Prescribing Guidelines
SUMMARY: The importance and significance of a February 2014 JAMA Internal Medicine article about Multaq is presented well by this report, “Dronedarone and Clinical Guidelines: A Dark Chapter That Must Be Reread”, that was published on the Medscape website.
To read more of this article, click below:
The story of how a marginally effective and perhaps even hazardous drug made it to first-line status of major guideline documents is a hard image to revisit. Also difficult to look back at were the lavish steakhouse dinners, the webinars, the “sponsored” programs, and then the result: legions of general cardiologists and primary-care doctors prescribing [Multaq (dronedarone)] en masse. With [Multaq (dronedarone)], for a time at least, hype trounced science…. [emphasis added]
We know, now, since being approved by the FDA in 2009 and soon becoming an often-prescribed atrial fibrillation drug, Multaq has been associated with increased risks of serious side effects, including liver failure, interstitial lung disease (ILD), stroke, and sudden cardiac death.[Read this article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Multaq Associated Lung Disease And Pulmonary Toxicity Pointed Out By New Safety Warnings In September 2012 Revised Label
- Sanofi Heart Drug Multaq Found To Be Dangerous For Patients With Permanent Atrial Fibrillation
- European Medicines Agency (EMA) Recommends Multaq Use Should Be Restricted For Safety Reasons
- Multaq: August 2011 Update: Another Liver Failure Case Report Article In Medical Journal
- Multaq Cardiovascular Deaths Overshadow Earlier Liver Injury Concerns For Drug Regulators
- Sanofi Heart Medication Multaq Has Constantly Been On FDA’s Radar During 2010 And 2011
- Multaq Update: European Safety Review Expanded To Cardiovascular Side Effects Risk In July 2011
- Sanofi-Aventis “Dear Doctor” Letter Will Warn Heart Drug Multaq Associated With Liver Failure